<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277936</url>
  </required_header>
  <id_info>
    <org_study_id>VEPP_200218</org_study_id>
    <nct_id>NCT04277936</nct_id>
  </id_info>
  <brief_title>Pharmacologic Modulation of Hippocampal Activity in Psychosis</brief_title>
  <official_title>Pharmacologic Modulation of Hippocampal Activity in Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether administration of levetiracetam (LEV), a&#xD;
      commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal&#xD;
      hyperactivity. Specifically, we will utilize two functional magnetic resonance imaging (MRI)&#xD;
      techniques: 1) blood oxygen level dependence (BOLD) contrast will assess activity with a&#xD;
      visual scene processing task that engages the anterior hippocampus and 2) arterial spin&#xD;
      labeling (ASL) will assess baseline activity. This study will also assess whether patients&#xD;
      have improvement in their symptoms after receiving LEV. Previous studies in people with&#xD;
      psychotic disorders have shown that the hippocampus is hyperactive and more activity&#xD;
      correlates with worsening of clinical symptoms. Therefore, the aim of this study is to use an&#xD;
      intervention to further understand the underlying mechanisms of the hippocampus in psychosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was redesigned and submitted as a new protocol (NCT04559529).&#xD;
  </why_stopped>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hippocampal Activity (Arterial Spin Labeling [ASL] Study)</measure>
    <time_frame>2 hours and 2 weeks after administration</time_frame>
    <description>Change in ASL signal after drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hippocampal Recruitment (BOLD Study)</measure>
    <time_frame>2 hours and 2 weeks after administration</time_frame>
    <description>Change in BOLD signal after drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Symptoms</measure>
    <time_frame>2 weeks after administration</time_frame>
    <description>Change in eye-tracking relational memory task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Symptoms</measure>
    <time_frame>2 weeks after administration</time_frame>
    <description>Change PANSS score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Schizophrenia; Psychosis</condition>
  <arm_group>
    <arm_group_label>Levetiracetam (LEV) 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam 500 mg</intervention_name>
    <description>Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.</description>
    <arm_group_label>Levetiracetam (LEV) 500 mg</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for psychosis subjects:&#xD;
&#xD;
          1. Men and women age 18 - 65.&#xD;
&#xD;
          2. Communicative in English.&#xD;
&#xD;
          3. Provide voluntary, written informed consent.&#xD;
&#xD;
          4. Physically healthy by medical history.&#xD;
&#xD;
          5. BMI &gt; 17.5 and &lt; 45.&#xD;
&#xD;
          6. Diagnosis of a psychotic disorder confirmed by Structured Clinical Interview for DSM-V&#xD;
             (SCID) or diagnostic interview with a trained clinician.&#xD;
&#xD;
          7. Stable medication regimen over at least the past two weeks, including the use of&#xD;
             either an oral or intramuscular administration of an antipsychotic medication.&#xD;
&#xD;
          8. For females, no longer of child-bearing potential, or agreeing to practice effective&#xD;
             contraception during the study; and,&#xD;
&#xD;
          9. For females of child-bearing potential, must have negative urine pregnancy test at&#xD;
             time of screening visit and before each testing day.&#xD;
&#xD;
         10. Not breastfeeding/nursing at time of screening or at any time during the study.&#xD;
&#xD;
        Inclusion criteria for healthy controls All of the above except for subjects will be&#xD;
        psychiatrically healthy and not taking psychotropic or potentially psychoactive&#xD;
        prescription medication.&#xD;
&#xD;
        Exclusion criteria for psychosis subjects&#xD;
&#xD;
          1. Age less than 18 or greater than 65.&#xD;
&#xD;
          2. Not communicative in English.&#xD;
&#xD;
          3. Unable to provide written informed consent.&#xD;
&#xD;
          4. Current medical or neurological illness.&#xD;
&#xD;
          5. History of severe head trauma.&#xD;
&#xD;
          6. BMI &lt; 17.5 or &gt; 45.&#xD;
&#xD;
          7. Meets criteria for diagnosis of substance or alcohol use disorder within the past&#xD;
             month.&#xD;
&#xD;
          8. Positive urine pregnancy test at time of screening, before each testing day, or any&#xD;
             potential concern for pregnancy at any time during the study.&#xD;
&#xD;
          9. Breastfeeding/nursing at time of screening or at any time during the study.&#xD;
&#xD;
         10. Conditions that preclude MR scanning&#xD;
&#xD;
         11. Conditions that preclude study drug administration&#xD;
&#xD;
        Exclusion criteria for healthy controls&#xD;
&#xD;
        All of the above and in addition:&#xD;
&#xD;
          1. Current use of psychotropic or potentially psychoactive prescription medication.&#xD;
&#xD;
          2. Major psychiatric disorder as determined by DSM-V (major depression, bipolar disorder,&#xD;
             obsessive compulsive disorder, post-traumatic stress disorder, etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <results_first_submitted>June 15, 2021</results_first_submitted>
  <results_first_submitted_qc>July 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2021</results_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Stephan Heckers</investigator_full_name>
    <investigator_title>Department Chair</investigator_title>
  </responsible_party>
  <keyword>Hippocampus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT04277936/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT04277936/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Levetiracetam (LEV) 500 mg</title>
          <description>Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.&#xD;
Levetiracetam 500 mg: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data were collected for a single subject, but study design was changed and study was discontinued. No data were analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>Levetiracetam (LEV) 500 mg</title>
          <description>Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.&#xD;
Levetiracetam 500 mg: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hippocampal Activity (Arterial Spin Labeling [ASL] Study)</title>
        <description>Change in ASL signal after drug administration</description>
        <time_frame>2 hours and 2 weeks after administration</time_frame>
        <population>Data were collected for a single subject, but study design was changed and study was discontinued.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam (LEV) 500 mg</title>
            <description>Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.&#xD;
Levetiracetam 500 mg: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.</description>
          </group>
        </group_list>
        <measure>
          <title>Hippocampal Activity (Arterial Spin Labeling [ASL] Study)</title>
          <description>Change in ASL signal after drug administration</description>
          <population>Data were collected for a single subject, but study design was changed and study was discontinued.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hippocampal Recruitment (BOLD Study)</title>
        <description>Change in BOLD signal after drug administration</description>
        <time_frame>2 hours and 2 weeks after administration</time_frame>
        <population>Data were collected for a single subject, but study design was changed and study was discontinued.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam (LEV) 500 mg</title>
            <description>Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.&#xD;
Levetiracetam 500 mg: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.</description>
          </group>
        </group_list>
        <measure>
          <title>Hippocampal Recruitment (BOLD Study)</title>
          <description>Change in BOLD signal after drug administration</description>
          <population>Data were collected for a single subject, but study design was changed and study was discontinued.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Symptoms</title>
        <description>Change in eye-tracking relational memory task</description>
        <time_frame>2 weeks after administration</time_frame>
        <population>No data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam (LEV) 500 mg</title>
            <description>Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.&#xD;
Levetiracetam 500 mg: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Symptoms</title>
          <description>Change in eye-tracking relational memory task</description>
          <population>No data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Symptoms</title>
        <description>Change PANSS score</description>
        <time_frame>2 weeks after administration</time_frame>
        <population>Healthy participant; outcome measure does not apply</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam (LEV) 500 mg</title>
            <description>Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.&#xD;
Levetiracetam 500 mg: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Symptoms</title>
          <description>Change PANSS score</description>
          <population>Healthy participant; outcome measure does not apply</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks The protocol is: a) single dose of 500mg LEV, b) neuroimaging session #1, c) 500mg LEV for 2-weeks and d) imaging session #2. This participant only took a single 500mg dose and never advanced to the protocol components c) and d), i.e. did not complete the study protocol. 93% of LEV is cleared in 48 hours, so monitoring is not necessary beyond 1 week.</time_frame>
      <desc>no adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Levetiracetam (LEV) 500 mg</title>
          <description>Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.&#xD;
Levetiracetam 500 mg: Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephan Heckers</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6159222665</phone>
      <email>stephan.heckers@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

